Results 281 to 290 of about 150,149 (335)

A Patient‐Derived Organoid Biobank of Adamantinomatous Craniopharyngioma as a Platform for Drug Discovery

open access: yesAdvanced Science, Volume 13, Issue 7, 3 February 2026.
This study successfully establishes adamantinomatous craniopharyngioma (ACP) patient‐derived organoids (PDOs) that preserve the histopathological and genetic features of the original tumors. Through drug sensitivity assays and subsequent mechanistic analyses, the study demonstrates that Ceritinib exerts its inhibitory effects on ACP PDO growth by ...
Huarong Zhang   +15 more
wiley   +1 more source

Promoting Autophagy Mitigates Stress‐Induced Remodeling in Patient iPSC‐CMs with the Phospholamban R9C Mutation

open access: yesAdvanced Science, Volume 13, Issue 7, 3 February 2026.
The Phospholamban (PLN) R9C mutation reduces SERCA2a binding, increasing calcium recycling and baseline contractility. However, the excess of free PLN promotes pentamer formation, limiting phosphorylation and blunting β‐adrenergic signaling. Under cardiac stress, enhanced functional demands overwhelm proteostasis in PLN R9C cells, leading to misfolded ...
Qi Yu   +10 more
wiley   +1 more source

CSNK1D inhibition suppresses head and neck squamous cell carcinoma progression through SHH and PTCH1 pathway. [PDF]

open access: yesCell Death Dis
Yang L   +11 more
europepmc   +1 more source

Engineering an Anaerobic Microenvironment to Empower Hydrogenase‐Catalyzed Hydrogen Therapy for Diabetic Wound Healing

open access: yesAggregate, Volume 7, Issue 2, February 2026.
A smart peptide hydrogel integrated with light‐responsive silver nanoclusters establishes a localized anaerobic niche, enabling hydrogenase function in oxygen‐rich biological environments. The system achieves sustained visible‐light‐driven H2 production, effectively scavenges reactive oxygen species, modulates immune responses, and significantly ...
Haishuo Ji   +15 more
wiley   +1 more source

An Anoikis Resistance Phenotype Converged to Immune Dysfunction and Resistance to Immune Checkpoint Blockades in Gastric Cancer

open access: yesCancer Innovation, Volume 5, Issue 1, February 2026.
Gastric cancer (GC) has high global incidence and mortality, with most cases diagnosed at advanced stages. Immunotherapy, particularly immune checkpoint blockers (ICBs), has shown promise, but not all patients benefit. This study applied consensus clustering based on anoikis‐related genes (ANRGs) to classify GC into two subclusters.
Xing Cai   +5 more
wiley   +1 more source

Home - About - Disclaimer - Privacy